
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd is experiencing a positive outlook due to its robust pipeline of drug candidates, particularly the successful Phase 3 results of brepocitinib for dermatomyositis, which is projected to disrupt the current market dominated by cumbersome intravenous therapies. The recent revision of revenue estimates for IMVT-1402 in Graves' Disease underscores the strong market positioning and competitive efficacy of Roivant's drug portfolio. Additionally, the unique disease-modifying potential of batoclimab positions Roivant favorably in the growing competitive landscape, further enhancing investor confidence in the company's capability for successful commercialization and long-term growth.
Bears say
Roivant Sciences Ltd faces a negative outlook primarily due to the failure of several key drug candidates, notably brepocitinib and IMVT assets, in critical clinical trials, which raises concerns about the company's capability to deliver successful therapeutics. This is compounded by ongoing challenges in the development of other treatments within its pipeline, particularly for high-unmet need indications, which could diminish investor confidence and future revenue streams. Additionally, the risks associated with off-target effects in mechanisms like TSHR antagonism further complicate the therapeutic landscape, suggesting potential setbacks in drug efficacy and safety profiles.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares